Mankind Pharma Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 07, 2025
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mankind Pharma held its 34th Annual General Meeting on August 7, 2025, via video conferencing from 3:30 PM to 5:13 PM IST, with 126 members participating. Four ordinary resolutions were put to e-vote: adoption of standalone and consolidated audited financial statements for FY ending March 31, 2025; re-appointment of Mr. Sheetal Arora (CEO and Whole-time Director) who retires by rotation; appointment of M/s. Amit Gupta & Associates as Secretarial Auditors; and ratification of the cost auditor's remuneration for FY 2025-26. The Chairman, Mr. Ramesh Juneja, noted that the Statutory and Secretarial Auditors' Reports contained no qualifications or adverse observations. Global CFO Mr. Ashutosh Dhawan presented an overview of FY 2024-25 financials to members, and the board acknowledged outgoing Independent Director Mr. Surendra Lunia. The actual e-voting results along with the scrutiniser's consolidated report will be filed with the exchanges within the stipulated timeline.
This is a routine procedural disclosure required by SEBI listing rules. No material new information is being shared — the actual voting outcomes will follow in a separate filing. Shareholders should wait for the e-voting results for confirmation of each resolution's approval status.